A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results

被引：95

作者：

Wohl, David ^{[1
]}

Oka, Shinichi ^{[2
]}

Clumeck, Nathan ^{[3
]}

Clarke, Amanda ^{[4
]}

Brinson, Cynthia ^{[5
]}

Stephens, Jeffrey ^{[6
]}

Tashima, Karen ^{[7
]}

Arribas, Jose R. ^{[8
]}

Rashbaum, Bruce ^{[9
]}

Cheret, Antoine ^{[10
]}

Brunetta, Jason ^{[11
]}

Mussini, Cristina ^{[12
]}

Tebas, Pablo ^{[13
,14
]}

Sax, Paul E. ^{[15
,16
,17
]}

Cheng, Andrew ^{[18
]}

Zhong, Lijie ^{[18
]}

Callebaut, Christian ^{[18
]}

Das, Moupali ^{[18
]}

Fordyce, Marshall ^{[18
]}

机构：

[1] Univ N Carolina, Dept Med, CB 7030,Bioinformat Bldg,130 Mason Farm Rd, Chapel Hill, NC 27599 USA

[2] Natl Ctr Global Hlth & Med, AIDS Clin Ctr, Tokyo, Japan

[3] CHU St Pierre Univ Hosp Brussels, Dept Infect Dis, Brussels, Belgium

[4] Brighton & Sussex Univ Hosp NHS Trust, Elton John Ctr, Brighton, E Sussex, England

[5] Cent Texas Clin Res, Austin, TX USA

[6] Mercer Univ, Sch Med, Dept Internal Med, Macon, GA 31207 USA

[7] Brown Univ, Miriam Hosp, Alpert Med Sch, Providence, RI USA

[8] Hosp Univ La Paz, IdiPAZ, Internal Med Serv, Infect Dis Unit, Madrid, Spain

[9] Capital Ctr Travel & Trop Med, Washington, DC USA

[10] Ctr Hosp Tourcoing Descartes Univ, Necker Hosp, Le Kremlin Bicetre Hosp, AP HP,Infect Dis Unit,Internal Med Unit, Paris, France

[11] Univ Toronto, Dept Family & Community Med, Maple Leaf Res, Med, Toronto, ON M5S 1A1, Canada

[12] Univ Modena & Reggio Emilia, Clin Malattie Infett & Tropicali, Modena, Italy

[13] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA

[14] Univ Penn, Perelman Sch Med, Ctr AIDS Res, Philadelphia, PA 19104 USA

[15] Brigham & Womens Hosp, Div Infect Dis, 75 Francis St, Boston, MA 02115 USA

[16] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA

[17] Harvard Univ, Sch Med, Boston, MA USA

[18] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA

来源：

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 2016年 / 72卷 / 01期

关键词：

tenofovir alafenamide; integrase inhibitor; randomized controlled trial; HIV; bone mineral density; renal safety; ANTIRETROVIRAL-NAIVE; ABACAVIR-LAMIVUDINE; EFAVIRENZ; THERAPY; DENSITY; SAFETY;

D O I：

10.1097/QAI.0000000000000940

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

In 2 double-blinded Phase 3 trials, 1733 antiretroviral-naive participants were randomized to tenofovir alafenamide (TAF), a tenofovir prodrug versus tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir/cobicistat/emtricitabine (E/C/F). At 96 weeks, 86.6% in the TAF arm and 85.2% in the TDF arm had HIV-1 RNA <50 c/mL [difference 1.5%; (95% CI: -1.8% to 4.8%)]. With TAF, there are smaller declines in bone mineral density and more favorable changes in proteinuria, albuminuria, and tubular proteinuria, and no cases of proximal tubulopathy compared with 2 for TDF. These longer-term data support E/C/F/TAF as a safe, welltolerated, and durable regimen for initial HIV-1 treatment.

引用

页码：58 / 64

页数：7

共 50 条

[31] Switching from a regimen containing abacavir/lamivudine or emtricitabine/tenofovir disoproxil fumarate to emtricitabine/tenofovir alafenamide fumarate does not affect central nervous system HIV-1 infection
Yilmaz, Aylin
Mellgren, Asa
Fuchs, Dietmar
Nilsson, Staffan
Blennow, Kaj
Zetterberg, Henrik
Gisslen, Magnus
INFECTIOUS DISEASES, 2019, 51 (11-12) : 838 - 846
[32] A Randomized Study of Tenofovir Disoproxil Fumarate in Treatment-experienced HIV-1 Infected Adolescents
Della Negra, Marinella
de Carvalho, Aroldo Prohmann
de Aquino, Maria Zilda
Nolasco da Silva, Marcos Tadeu
Pinto, Jorge
White, Kirsten
Arterburn, Sarah
Liu, Ya-Pei
Enejosa, Jeffrey V.
Cheng, Andrew K.
Chuck, Steven L.
Rhee, Martin S.
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2012, 31 (05) : 469 - 473
[33] HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Initiating Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate: A Subanalysis of ALLIANCE Data
D'Antoni, Michelle L.
Andreatta, Kristen
Chang, Silvia
Cox, Stephanie
Hindman, Jason T.
Avihingsanon, Anchalee
Martin, Hal
Vanderveen, Laurie A.
Callebaut, Christian
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2024, 96 (04) : 380 - 384
[34] Rare emergence of drug resistance in HIV-1 treatment-naive patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
Margot, Nicolas A.
Kitrinos, Kathryn M.
Fordyce, Marshall
McCallister, Scott
Miller, Michael D.
Callebaut, Christian
HIV CLINICAL TRIALS, 2016, 17 (02): : 78 - 87
[35] Rare emergence of drug resistance in HIV-1 treatment-naive patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for 144 weeks
Margot, Nicolas
Cox, Stephanie
Das, Moupali
McCallister, Scott
Miller, Michael D.
Callebaut, Christian
JOURNAL OF CLINICAL VIROLOGY, 2018, 103 : 37 - 42
[36] A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients
Eron, Joseph J.
Orkin, Chloe
Gallant, Joel
Molina, Jean-Michel
Negredo, Eugenia
Antinori, Andrea
Mills, Anthony
Reynes, Jacques
Van Landuyt, Erika
Lathouwers, Erkki
Hufkens, Veerle
Jezorwski, John
Vanveggel, Simon
Opsomer, Magda
AIDS, 2018, 32 (11) : 1431 - 1442
[37] Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial
Soriano, Vicente
Arasteh, Keikawus
Migrone, Horacio
Lutz, Thomas
Opravil, Milos
Andrade-Villanueva, Jaime
Antunes, Francisco
Di Perri, Giovanni
Podzamczer, Daniel
Taylor, Steve
Domingo, Pere
Gellermann, Holger
de Rossi, Lothar
ANTIVIRAL THERAPY, 2011, 16 (03) : 339 - 348
[38] A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults
Huhn, Gregory D.
Tebas, Pablo
Gallant, Joel
Wilkin, Timothy
Cheng, Andrew
Yan, Mingjin
Zhong, Lijie
Callebaut, Christian
Custodio, Joseph M.
Fordyce, Marshall W.
Das, Moupali
McCallister, Scott
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2017, 74 (02) : 193 - 200
[39] Renal profile of patients treated with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort
Rotea-Salvo, Sandra
Martinez-Pradeda, Alejandro
Fernandez-Oliveira, Carla
Gimenez-Arufe, Victor
Balboa-Barreiro, Vanesa
Margusino-Framinan, Luis
Mena-De-Cea, Alvaro
Vazquez-Rodriguez, Pilar
Castro-Iglesias, Angeles
Lopez-Calvo, Soledad
Martin-Herranz, Isabel
Miguez-Rey, Enrique
Cid-Silva, Purificacion
EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2023, 30 (04) : 221 - 226
[40] Switching From Twice-Daily Raltegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine to Once-Daily Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed, HIV-1-Infected Subjects: 48 Weeks Data
Mills, A.
Crofoot, G.
Ortiz, R.
Rashbaum, B.
Towner, W.
Ward, D.
Brinson, C.
Kulkarni, R.
Garner, W.
Ebrahimi, R.
Cao, H.
Cheng, A.
Szwarcberg, J.
HIV CLINICAL TRIALS, 2014, 15 (02): : 51 - 56

← 1 2 3 4 5 →